Napolitano Janet 4

What Happened
Janet Napolitano, a director of Vir Biotechnology (VIR), reported the sale of 3,200 shares on June 1, 2026. The shares were disposed at $9.45 each for a total transaction value of $30,240. This was a sale (not a purchase) and thus is typically considered routine insider selling rather than a direct bullish signal.

Key Details

• Transaction date and price: June 1, 2026 — 3,200 shares sold at $9.45 per share (total $30,240).
• Report filed: Form 4 filed June 2, 2026 (appears timely).
• Post-transaction holdings: Not disclosed in the summary provided in your request.
• Transaction type/code: Reported as an open-market/private sale (Code S).
• Footnote: Sale was effected under a pre-established Rule 10b5-1 trading plan adopted by the reporting person on June 27, 2025 (per footnote F1).

Context
Sales executed under a Rule 10b5-1 plan are prearranged and often reflect scheduled or formulaic dispositions, which can make them less informative about the insider’s current view of the company. For retail investors, purchases are generally more indicative of insider conviction than routine sales; this reported transaction is small in value and was done via a 10b5-1 plan.